Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome
, , , , und
17. März 2022
Über diesen Artikel
Online veröffentlicht: 17. März 2022
Seitenbereich: 56 - 65
Eingereicht: 22. Juni 2021
DOI: https://doi.org/10.2478/rjim-2021-0034
Schlüsselwörter
© 2022 Hasan H. Yeter et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Yeter, Hasan H.
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Derici, Ulver
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Arinsoy, Turgay
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Altok, Kadriye
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Erten, Yasemin
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Guz, Galip
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey